Effects of TNF-Alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Trial Profile

Effects of TNF-Alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 May 2016

At a glance

  • Drugs Etanercept (Primary)
  • Indications Psoriasis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Apr 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 25 Jun 2013 Planned end date changed from 1 Dec 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top